RP-323 is under clinical development by PhorMed and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RP-323’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RP-323 overview

RP-323 (TPA) is under development for the treatment of acute myelocytic leukemia (AML) in refractory patients, Hodgkin’s lymphoma, Parkinson's disease, stroke, COVID-19 associated acute respiratory distress syndrome (ARDS) and unspecified indication. It is administered through intravenous route. The drug candidate is 12-O-tetradecanoylphorbol-13-acetate which is a naturally occurring compound. It acts by targeting protein kinase C. It was also under development for the treatment of chronic myelocytic leukemia (CML, chronic myeloid leukemia), acute leukemia, non-Hodgkin lymphoma, aplastic anemia, chronic lymphocytic leukemia (CLL), myeloproliferative disorders and multiple myeloma (Kahler's disease) and myelodysplastic syndrome (MDS).

PhorMed overview

PhorMed is a clinical stage biopharmaceutical company developing RP-323, a gene repair therapy. PhorMed is headquartered in Beverly Hills, California, the US.

For a complete picture of RP-323’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.